	With the onset of the COVID-19 pandemic, clinical trial sponsor companies and CROs hastened to implement virtual trial technologies. The virtual visits and digital data exchange would enable them to start or continue studies, despite government mandates requiring patients and staff to stay at home.

	During the COVID-19 lockdown, in April and May 2020, ERT surveyed clinical professionals on how the demands of the pandemic were affecting their organizations’ use and planned use of virtual trial technologies. Download the free eBook, Virtual Trials and the COVID-19 Pandemic: The State of Clinical Trials, to learn about their responses and industry trends.

		Organizations will increasingly run full or hybrid virtual clinical trials moving forward because of associated improvements in patient engagement, timeframes, cost effectiveness and data fidelity.

		82% of clinical trial professionals polled stated that their organizations are incorporating elements of virtual clinical trials due to the pandemic.

		The biggest issue keeping participants up at night is screening for new clinical trials patients (79%)

		The most common ways to collect data in a virtual clinical trial are telehealth (75%) and patient-used devices (75%)

		The primary issues impacting trials over the next six to twelve months are trial management (32%) and patient recruitment and enrollment (25%)